立体定向放疗治疗八九十岁早期肺癌患者的安全性与疗效
基于5家机构1083例原发性肺癌SBRT数据库,比较<70岁、70-79岁和≥80岁患者结局。≥80岁患者2年局部复发、区域复发、远处转移和肿瘤特异性生存与年轻患者无差异,但2年总生存较低;3级以上放射性肺炎发生率无差异。结论认为SBRT对≥80岁早期肺癌患者安全有效。
要点
- ≥80岁与年轻患者SBRT后2年局部复发、区域复发、远处转移和CSS均无显著差异。
- ≥80岁患者2年OS显著低于年轻组,但3级以上放射性肺炎发生率无差异。
- 早期肺癌患者无论年龄均应考虑SBRT治疗。
核心结论
- SBRT对≥80岁早期肺癌患者是安全的治疗方式,肿瘤控制结局与年轻患者相当。
- 所有早期肺癌患者无论年龄均应考虑接受SBRT治疗。
研究设计与样本
- 多机构(5家机构)数据库回顾性分析,共1083例接受SBRT的原发性肺癌患者。
- 按年龄分为<70岁(305例,28%)、70-79岁(448例,41%)和≥80岁(330例,30%)三组进行比较。
- 中位随访1.7年(范围1-10年),中位年龄75岁(范围41-94岁)。
- 局部复发、区域复发和远处转移采用竞争风险法计算,CSS和OS采用Kaplan-Meier法计算。
主要发现
- 三组2年局部复发率分别为4.2%、5.4%、3.7%(P=.7),无显著差异。
- 三组2年区域复发率分别为10.4%、7.8%、5.3%(P=.1),无显著差异。
- 三组2年远处转移率分别为12.2%、7.7%、9.5%(P=.2),无显著差异。
- 三组2年CSS分别为90.6%、90.3%、90.4%(P=.6),无显著差异。
- ≥80岁组2年OS显著较低(73.6% vs 67.2% vs 63.3%,P<.01)。
关键数值与推荐
- 3级以上放射性肺炎发生率在<70岁、70-79岁、≥80岁组分别为1.3%、1.6%、1.5%(P=1.0)。
- 90天死亡率在<70岁、70-79岁、≥80岁组分别为1.3%、2.5%、2.4%(P=.01)。
- 在≥80岁患者中,OS与T分期相关(风险比1.7;P<.01)。
临床怎么用
- 对≥80岁早期肺癌患者,SBRT可作为安全有效的治疗选择,不应仅因年龄排除。
- ≥80岁患者总生存较低,治疗决策时需结合T分期等预后因素综合评估。
局限性
- 回顾性多机构数据库研究,中位随访仅1.7年。
- 原文未报告具体SBRT剂量方案和肿瘤体积数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the safety and efficacy of lung stereotactic body radiation therapy (SBRT) in octo- and nonagenarians and to compare their outcomes with those of younger patients. METHODS AND MATERIALS: Patients with primary lung cancer treated with SBRT were identified from a multi-institutional (5 institutions) database of 1083 cases. Details of patient factors, treatment specifics, toxicity, and clinical outcomes were extracted from the database. All events were calculated from the end of radiation therapy. Estimates of local recurrence, regional recurrence, and distant metastases were calculated using the competing risk method. Cause-specific survival (CSS) and overall survival (OS) were calculated using the Kaplan-Meier method. Outcomes were compared for those aged <70, 70 to 79, and ≥80 years. Univariable and multivariable analyses were performed to determine associations with CSS and OS in patients aged ≥80 years. RESULTS: The median (range) follow-up was 1.7 (1-10) years, and median age was 75 (41-94) years. There were 305 patients aged <70 years (28%), 448 aged 70 to 79 years (41%), and 330 aged ≥80 years (30%). There was no difference in 2-year local recurrence (4.2% vs 5.4% vs 3.7%, respectively, P=.7), regional recurrence (10.4% vs 7.8% vs 5.3%, P=.1), distant metastases (12.2% vs 7.7% vs 9.5%, P=.2), or CSS (90.6% vs 90.3% vs 90.4%, P=.6). Those aged ≥80 years had significantly lower 2-year OS (73.6% vs 67.2% vs 63.3%, P<.01). The grade 3+ pneumonitis rate was 1.3% versus 1.6% versus 1.5% (P=1.0) in patients aged <70, 70 to 79, and ≥80 years, respectively. The 90-day mortality rates for patients aged <70, 70 to 79, and ≥80 years were 1.3%, 2.5%, and 2.4% (P=.01), respectively. In patients aged ≥80 years OS was associated with T category (hazard ratio 1.7; P<.01). CONCLUSION: Stereotactic body radiation therapy is a safe treatment modality in elderly patients (aged ≥80 years). Despite larger tumor volumes, the tumor control outcomes were comparable to those in younger patients treated with SBRT. All patients with early-stage lung cancer, regardless of age, should be considered for treatment with SBRT.
引用
- Giuliani M, Hope A, Guckenberger M, et al. Stereotactic Body Radiation Therapy in Octo- and Nonagenarians for the Treatment of Early-Stage Lung Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28258901. doi:10.1016/j.ijrobp.2017.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。